Bringing the patient's perspectives forward in drug development and health-care evaluation

Phenomenology: A Method for the Interpretation of Patient-Reported Outcomes

Patient-reported outcome measures (PROMs) play a central role in clinical research and patient care resulting in a plethora of standardized PROMs to measure a range of constructs, including disease symptoms, health-related quality of life, and health status (Meadows/Reaney) used in a range of settings, including the nursing environment. However, the use of PROMs in drug development and their use in healthcare evaluation do not easily marry together. In drug development, standardization of measurement is key to the interpretation of the formation at a population level with minimal biases. However, in health care, the individual patient perspective, priority, and needs should be taken into account whereas, in the clinical encounter, one has to also deal with what is particular and unique. The purpose of this paper is to describe the characteristics of the phenomenological method as a means within a mixed-method framework, to supplement participants' patient-reported outcome numeric scores with a more in-depth commentary on the essence of the lived health experiences.

Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen?

INTRODUCTION

An avalanche of early stage cancer clinical trials is coming. The majority of these solely use surrogate outcomes that have not been validated against a target outcome of interest (e.g. overall survival). Current HTA guidance on surrogate outcome validation are not methodologically or practically conducive to this scenario.

AREAS COVERED

We provide a high-level overview of methods, approaches, and conceptual thinking for making better use of limited evidence within early stage cancer HTA submissions. We outline regulatory and HTA issues and emphasize how evidence transitions from one to another, what major gaps currently exist, and how these may be bridged. We summarize current methodologies and practices, their pros and cons. We outline how complementary measurements strengthen evaluations and address fallacies and biases of conventional statistical methods for surrogate outcomes validation. The value of real-world data to support some of the necessary validity components is discussed. Lastly, we address the importance of the patient voice for better understanding which surrogate outcomes may appropriately inform HTA.

EXPERT OPINION

Conventional surrogate outcome validation represents a fraught and sub-optimal framework for HTA purposes, particularly for early stage cancer. Tools for optimizing use of limited evidence exist. Education of stakeholders is highly needed.

Story completion (SC) - an epistemological approach to the interpretation of patient-reported outcomes?

INTRODUCTION

Patient-reported outcome measures (PROMs) quantitative data are increasingly accompanied by qualitative narrative data, which does not always provide the insights required to inform healthcare.

AREAS COVERED

This perspective considers how story completion (SC) may be used to gain a deeper insight on people's experiences and guide interpretation of the meaning of PROM responses.

EXPERT OPINION

Story completion (SC) is an epistemological approach involving participants telling a story in response to a pre-determined 'stem' they have been presented with.

Quality of Life Measurements from the Patient Perspective: Capturing the Heterogeneity of the Patient Experience in a Standardised Way

For patients, quality of life is the confluence and interaction of multiple factors related to both the disease and to how life is lived with and beyond the disease. When tasked with completing a quality-of-life questionnaire, patients may well wonder for whose benefit this is, which really needs to be made clear. We discuss some of the issues around quality-of-life questionnaires and the challenge of the heterogeneity of the patient experience. PATIENT SUMMARY: This mini-review discusses quality-of-life measurements from the patient perspective and the need to take account of the patient's life and not just the disease.